Analysis Of Income And Expense [Abstract]

Zealand Pharma - Filing #1440145

Concept 2020-01-01 to
2020-12-31
2019-01-01 to
2019-12-31
2018-01-01 to
2018-12-31
Analysis of income and expense [abstract]
Revenue [abstract]
Revenue
353,314,000 DKK
41,333,000 DKK
37,977,000 DKK
Material income and expense [abstract]
Royalty expense
0 DKK
415,000 DKK
3,356,000 DKK
Research and development expense
604,081,000 DKK
561,423,000 DKK
438,219,000 DKK
Other operating income (expense)
36,997,000 DKK
444,000 DKK
1,099,526,000 DKK
Operating expense
1,092,107,000 DKK
629,304,000 DKK
481,762,000 DKK
Sales and marketing expense
285,256,000 DKK
0 DKK
0 DKK
Comprehensive income, continuing and discontinued operations [abstract]
Comprehensive income
837,752,000 DKK
571,541,000 DKK
581,278,000 DKK
Comprehensive income attributable to owners of parent, continuing and discontinued operations [abstract]
Comprehensive income, attributable to owners of parent
837,752,000 DKK
571,541,000 DKK
581,278,000 DKK

Talk to a Data Expert

Have a question? We'll get back to you promptly.